Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archopht.1962.00960020089010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring SERPINA3 as a neuroinflammatory modulator in Alzheimer's disease with sex and regional brain variations.
Metab Brain Dis
January 2025
Department of Biomedical and Biotechnological Sciences, Human Anatomy and Histology Section, School of Medicine, University of Catania, Catania, Italy.
SERPINA3, a serine protease inhibitor, is strongly associated with neuroinflammation, a typical condition of AD. Its expression is linked to microglial and astrocytic markers, suggesting it plays a significant role in modulating neuroinflammatory responses. In this study, we examined the SERPINA3 expression levels, along with CHI3L1, in various brain regions of AD patients and non-demented healthy controls (NDHC).
View Article and Find Full Text PDFEpidemiological Features of Sinonasal Adenocarcinoma and Prognostic Nomogram: A Study Based on the SEER Database.
Cancer Control
January 2025
Department of Oncology, Suining Central Hospital, Suining, China.
Objective: Our study aimed to update demographic profiles of sinonasal adenocarcinoma (SNAC) between 2000 and 2020, identify independent prognostic risk factors, and devise a predictive nomogram for overall survival (OS).
Methods: Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, cases of SNAC from 2000 to 2020 were analyzed for incidence trends. Univariate and multivariate Cox regression models helped pinpoint factors impacting patient survival.
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update.
Cell Stem Cell
January 2025
Carpenter Consulting Corporation, Washington, USA. Electronic address:
Since the first derivation of human pluripotent stem cells (hPSCs) 27 years ago, technologies to control their differentiation and manufacturing have advanced immensely, enabling increasing numbers of clinical trials with hPSC-derived products. Here, we revew the landscape of interventional hPSC trials worldwide, highlighting available data on clinical safety and efficacy. As of December 2024, we identify 116 clinical trials with regulatory approval, testing 83 hPSC products.
View Article and Find Full Text PDFEngineered hiPSC-derived vascular graft brings hope for thrombosis-free vascular therapy.
Cell Stem Cell
January 2025
Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI, USA. Electronic address:
Tissue-engineered vascular conduits (TEVCs) are a promising blood vessel replacement. In a recent publication in Cell Stem Cell, Park et al. developed TEVCs comprised of decellularized human umbilical arteries lined with shear-trained, human induced pluripotent stem cell (hiPSC)-derived endothelial cells (ECs) that resisted thrombosis and exhibited patency upon grafting into the rat inferior vena cava (IVC).
View Article and Find Full Text PDFChromatin hubs drive key regulatory networks in leukemia.
Mol Cell
January 2025
Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. Electronic address:
In this issue of Molecular Cell, Gambi, Boccalatte, Hernaez, et al. apply multiomics followed by genetic engineering to define then characterize epigenetic hubs that regulate processes crucial for T-ALL and use this insight to offer new avenues for therapeutic targeting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!